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Dear Editor,
Over the past decades, data from randomized con-
trolled trials have conﬁrmed the use of pegylated in-
terferon alpha (peg-IFNα) plus ribavirin (RBV), as the 
mainstay of HCV therapy in adults (1). In children aged 
3 years and older, the Food and Drug administration in 
the United States did not approve the use of this combi-
nation therapy until December 2008, and for children in 
Europe, approval from the European Medicines Agency 
came a year later in September 2009. Current guidelines 
for adults suggest starting patients with clinically sig-
niﬁcant hepatic ﬁbrosis on this treatment, due to the 
high risk of cirrhosis. Conversely, in pediatric patients, 
the progression of the condition is slower and the out-
comes of the HCV infection are better, so the timing of 
when to start treatment remains controversial, and no 
guidelines are currently available for this age group. In 
addition, as children with chronic HCV infection (CHC) 
are usually asymptomatic and rarely develop severe liver 
damage, the possibility of eliciting adverse eﬀects from 
the current therapies must be balanced appropriately 
against the beneﬁts. On the other hand, eradicating HCV 
in order to avert potential hepatic complications in the 
future, including hepatocarcinoma in later life, is consid-
ered by some authors to be a justiﬁable reason to pursue 
antiviral therapy in younger individuals as well (2). 
The retrospective cohort study recently published in 
Hepatitis Monthly by Pawlowska et al, analyzed 119 and 51 
children with CHC who were treated with; non-pegylated 
IFNα plus RBV (group 1) or peg-IFNα plus RBV (group 2), 
respectively. Sustained viral response (SVR), was deﬁned 
as an undetectable level of HCV-RNA 24 weeks after the 
end of treatment, and this was achieved by 51% and 47% of 
patients from group 1 and group 2, respectively. In both 
groups, the hemoglobin levels as well as the leukocyte 
and platelet counts, both during treatment and follow-
ing 12 weeks of therapy, were lower in patients reaching 
SVR (3). The rate of SVR reported by the literature in pedi-
atric population for PEG-IFNα plus ribavirin therapy is set 
between 30 to 100% (1), which is comparable to the rate 
observed in adults (2). Among all the factors associated 
with a SVR, hemoglobin levels, along with leukocyte and 
platelet counts have previously been described in adult 
populations (4). However, in children, the interdepen-
dence between the SVR and such hematological charac-
teristics has not been examined in depth. In a previous 
study (5), Pawlowska et al, had observed a similar earlier 
response to therapy and ALT normalization in children 212 Hepat Mon. 2012
Vigano A SVR & Hematological Adverse Events 
treated with non-pegylated IFN-alpha and ribavirin who 
had a decreased leukocyte-count. The recently published 
study by the same authors has, in our opinion, two 
strong points. First, it conﬁrms and supports the compa-
rable eﬃcacy of the association of peg-IFNα plus RBV, ver-
sus IFNα plus RBV in the pediatric population, data that 
is consistent with those revised in the most recent adult 
guidelines. Secondly, it enhances the predictive role for 
those major hematological disorders, which are com-
monly considered to be only side eﬀects. 
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